Systemic and intravitreal Bevacizumab (Avastin®) in neovascular age-related macular degeneration

被引：1

作者：

Michels S. ^{[1
,2
]}

Prager F. ^{[1
]}

Geitzenauer W. ^{[1
]}

Lackner B. ^{[1
]}

Sacu S. ^{[1
]}

Weigert G. ^{[1
]}

Kriechbaum K. ^{[1
]}

Polak K. ^{[1
]}

Georgopoulos M. ^{[1
]}

Schmidt-Erfurth U. ^{[1
]}

机构：

[1] Klinik für Augenheilkunde und Optometrie, Medizinische Universität Wien

[2] Klinik für Augenheilkunde und Optometrie, Medizinische Universität Wien, 1090 Wien

来源：

Spektrum der Augenheilkunde | 2007年 / 21卷 / 3期

关键词：

Bevacizumab; Macular degeneration; Neovascularization; VEGF;

D O I：

10.1007/s00717-007-0203-3

中图分类号：

学科分类号：

摘要：

A number of experimental and clinical studies have show the important role of the vascular endothelial growth factor (VEGF) in most neovascular and exudative ocular diseases. The therapeutic concept of an anti-VEGF therapy has been most promising in a number of prospective controlled clinical trials. In the treatment of neovascular age-related macular degeneration (AMD) intravitreal antiVEGF therapy has shown not only to stabilize vision in most patients, but also to improve vision in a significant number of patients. Bevacizumab (Avastin®) is a monoclonal antibody designed to bind all isoforms of VEGF. It has been primarily developed for the systemic treatment of colon cancer in oncology. But several prospective and retrospective case series evaluating the use of systemic and intravitreal bevacizumab in neovascular AMD and other neovascular and exudative ocular diseases have shown most promising results. Despite the fact that results of large, prospective, long-term studies are currently unavailable, a number of studies have shown anatomic, functional and safety results up to 6 months similar to other anti-VEGF drugs. An approval of bevacizumab in ophthalmology by regulatory agencies cannot be expected in the near future. Similar to a number of drugs in clinical use, bevacizumab will remain available in ophthalmology only as off label treatment or in clinical trials. To clarify the role of bevacizumab for the treatment of a number of neovascular and exudative eye diseases, prospective long-term studies are necessary. © Springer-Verlag 2007.

引用

页码：154 / 159

页数：5

共 33 条

[1]

Folkman J., Role of angiogenesis in tumor growth and metastasis, Semin Oncol, 29, 6 SUPPL. 16, pp. 15-18, (2002)

[2]

Adamis A.P., Shima D.T., The role of vascular endothelial growth factor in ocular health and disease, Retina, 25, 2, pp. 111-118, (2005)

[3]

Ferrara N., Vascular endothelial growth factor: Molecular and biological aspects, Curr Top Microbiol Immunol, 237, pp. 1-30, (1999)

[4]

Lange T., Guttmann-Raviv N., Baruch L., Machluf M., Neufeld G., VEGF162, a new heparin-binding vascular endothelial growth factor splice form that is expressed in transformed human cells, J Biol Chem, 278, 19, pp. 17164-17169, (2003)

[5]

Plate K.H., Warnke P.C., Vascular endothelial growth factor, J Neurooncol, 35, 3, pp. 365-372, (1997)

[6]

Frank R.N., Amin R.H., Eliott D., Puklin J.E., Abrams G.W., Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes, Am J Ophthalmol, 122, 3, pp. 393-403, (1996)

[7]

Kliffen M., Sharma H.S., Mooy C.M., Kerkvliet S., De Jong P.T., Increased expression of angiogenic growth factors in age-related maculopathy, Br J Ophthalmol, 81, 2, pp. 154-162, (1997)

[8]

Okamoto N., Tobe T., Hackett S.F., Et al., Transgenic mice with increased expression of vascular endothelial growth factor in the retina: A new model of intraretinal and subretinal neovascularization, Am J Pathol, 151, 1, pp. 281-291, (1997)

[9]

Spilsbury K., Garrett K.L., Shen W.Y., Constable I.J., Rakoczy P.E., Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization, Am J Pathol, 157, 1, pp. 135-144, (2000)

[10]

Rosenfeld P.J., Brown D.M., Heier J.S., Et al., Ranibizumab for neovascular age-related macular degeneration, N Engl J Med, 355, 14, pp. 1419-1431, (2006)

← 1 2 3 4 →